Night sweats may be associated with severity of sleep apnea, claims study

A collaborative effort between the University of Córdoba and IMIBIC uses, for the first time, changes in sweat metabolism to diagnose the severity of sleep apnea.

In Greek, apnea (ἄπνοια) denotes the “absence of breathing.” Hence, obstructive sleep apnea is a disease defined by interruptions in breathing, which recurs while the person suffering from it is asleep. A feeling of breathlessness, fatigue and drowsiness are symptoms that patients suffer. This disease is also related to the incidence of cardiovascular disorders, so to deal with these related problems, adequate diagnosis of the severity of the disease is necessary.

Alterations in the metabolism of people with sleep apnea are key to determining the severity of the disease. These changes are usually analyzed in blood or urine. However, in search of a less invasive and more accessible alternative, a team from the Department of Analytical Chemistry at the University of Córdoba and the Maimonides Institute for Biomedical Research in Córdoba (IMIBIC), formed by researchers Laura Castillo, Mónica Calderón, Feliciano Priego and Bernabé Jurado, has verified, for the first time, the potential of sweat samples to ascertain the severity of sleep apnea.

“By analyzing sweat metabolome and its alterations, mainly at night, we were able to see what stage of the disease the patients were in,” explains Laura Castillo, the study’s lead author. For her, the advantages of using sweat over other samples are clear: “it is a non-invasive and clean sample since, unlike the case with blood, we don’t have to remove proteins, and it’s much easier to analyze and detect metabolites.”

In this study, sweat samples from before and after sleep were analyzed from a series of individuals with sleep apnea at different stages, as well as from a control group without the disease.

In these samples, using the gas chromatography technique, coupled with high-resolution mass spectrometry, 78 metabolites were identified and their changes were studied, mostly related to energy production and oxidative stress. “We could see how the sweat metabolism itself indicates those alterations during sleep as a result of which the person’s energy production worsens and their oxidative stress increases,” says Castillo. Thus, with a personalized follow-up using the sweat excreted during the sleep of a person with the disease, its development can be tracked, and its possible effects, such as cardiovascular problems, can be monitored. This metabolomic profile also made it possible, in the trial, to distinguish between those who suffered from the disease and those who did not have it and belonged to the control group.

An index to learn more about the disease

In addition to establishing sweat as a good sentinel when it comes to determining the stage of the disease, this work also reveals the importance of taking into account the oxygen desaturation index when diagnosing it.

The diagnosis of sleep apnea is currently based on the Apnea-Hypopnea Index (AHI), which measures sleep apnea based on the episodes of shortness of breath one suffers per hour (for example, the disease is severe when one has 30 or more episodes per hour). According to the team, this index “does not provide all the information about the disease or the patient’s situation at a given time” since it counts how many events there are, but not their severity.

Therefore, in their study they also verify the importance of using the oxygen desaturation index, which shows how serious the episodes are by measuring the number of events in which oxygen saturation has decreased by more than 3%. After verifying the linear relationship between this index and the AHI, its validity has been confirmed, since, in addition to the data provided by the AHI, it also measures severity, taking into account oxygen saturation loss.

Reference:

Laura S. Castillo-Peinado, Mónica Calderón-Santiago, Bernabé Jurado-Gámez, Feliciano Priego-Capote, Changes in human sweat metabolome conditioned by severity of obstructive sleep apnea and intermittent hypoxemia, Journal of Sleep Research, https://doi.org/10.1111/jsr.14075.

Powered by WPeMatico

Non-Invasive Predictive Model may Help in Early Detection of Endometriosis in Infertile Women: Study

A recent study by Jie Zhang and team have successfully crafted a non-invasive predictive model to identify minimal or mild endometriosis in patients who struggle with infertility. The findings were published in the Journal of Minimally Invasive Gynecology.

Infertility affects millions worldwide and identifying the underlying causes is a persistent challenge. By recognizing the significance of early detection in endometriosis-related infertility the team sought to develop a predictive model. This retrospective study was conducted at a tertiary referral center and enrolled a total of 1365 infertility patients who underwent laparoscopy between January 2013 and August 2020.

The study divided patients into a training set (n=910) for model development and a validation set (n=455) for confirmation. This in depth evaluation included sensitivities, specificities, AUCs, the Hosmer-Lemeshow goodness of fit test, NRIs, and IDIs. The final model demonstrated high accuracy by incorporating BMI, dysmenorrhea, dyspareunia, uterosacral tenderness, and serum CA-125. Sensitivities of 87.7% and 93.3%, specificities of 68.6% and 66.4%, and AUCs of 0.84 and 0.85 were recorded for the training and validation sets, respectively.

Uterosacral tenderness emerged as a pivotal predictor and the nomogram underscored good calibration and clinical value. This innovative model promises a cost-effective and less invasive means of identifying minimal or mild endometriosis, a significant factor in infertility.

This study delivers a reliable tool for clinicians as a crucial step towards personalized infertility care. Early identification is a key to prompt intervention which potentially revolutionize the landscape of infertility treatment. This is a significant advancement in empowering healthcare providers with a tool to enhance the diagnosis and treatment of infertility in women.

Source:

Zhang, J., Wang, J., Zhang, J., Liu, J., Xu, Y., Zhu, P., Dai, L., Shu, L., Liu, J., Hou, Z., Diao, F., Liu, J., & Mao, Y. (2023). Developing a predictive model for minimal or mild endometriosis as a clinical screening tool in infertile women: uterosacral tenderness as a key predictor. In Journal of Minimally Invasive Gynecology. Elsevier BV. https://doi.org/10.1016/j.jmig.2023.12.008

Powered by WPeMatico

Placental Pathology Linked to Impaired Brain Development in Neonates with Congenital Heart Disease: Study

In a revolutionary study, researchers have uncovered a concerning association between placental pathology and impaired brain development in neonates diagnosed with severe congenital heart disease. The findings, based on a prospective analysis of 96 term singleton pregnancies, shed light on the potential impact of placental health on the neurological outcomes of these vulnerable infants. The study suggests that placental pathology is common in neonates with severe congenital heart disease and may contribute to impaired brain development. The study results were published in the Journal of The American Heart Association. 

Infants born with congenital heart disease face a heightened risk of compromised brain development while still in the womb, making them susceptible to postnatal brain injuries and unfavorable long-term neurodevelopmental consequences. Recognizing the pivotal role of the placenta in fetal growth, researchers delved into the prevalence of placental pathology in cases of fetal congenital heart disease by examining how such pathology correlates with overall and regional brain volumes, gyrification, and post-birth occurrences of brain injury.

Also Read: Latest research redefines neurodevelopmental risks, outcomes for congenital heart disease

The study, conducted by a team of experts, aimed to assess the incidence of placental pathology and its correlation with postnatal brain development in neonates with congenital heart disease.

Findings:

  • The placental analyses revealed a strikingly high occurrence of various abnormalities, including maternal vascular malperfusion lesions (46%), nucleated red blood cells (37%), chronic inflammatory lesions (35%), delayed maturation (30%), and placental weight below the 10th percentile (28%).
  • To gauge the severity of placental pathology, the researchers employed a scoring system.
  • The results showed a negative correlation between the severity of placental abnormalities and multiple aspects of postnatal brain development.
  • Specifically, reductions in cortical gray matter, deep gray matter, brainstem, cerebellar, and total brain volumes were observed in neonates with more severe placental pathology.
  • Postnatal magnetic resonance imaging played a pivotal role in the analysis, allowing researchers to delve into the intricacies of brain structure, gyrification, and the presence of injuries.
  • The findings emphasized the comprehensive impact of placental health on various brain regions crucial for neurological development.
  • Importantly, the study revealed that the association between placental pathology severity and reduced brain volumes persisted even after adjusting for postmenstrual age at magnetic resonance imaging.
  • This suggests that the adverse effects of placental abnormalities on brain development are not solely dependent on the timing of imaging but are an independent factor influencing neurological outcomes.
Also Read: Study emphasizes vitamin D supplementation for all congenital melanocytic nevi patients during the winter months

The implications of this research are significant, highlighting the need for a holistic approach in managing neonates with congenital heart disease. By recognizing the frequent occurrence of placental pathology in this population and understanding its link to impaired brain development, healthcare providers can potentially intervene early to mitigate the long-term neurodevelopmental consequences. As we strive for improved outcomes in neonatal care, this study underscores the importance of considering the placenta as a key player in fetal development. Further research and clinical efforts are warranted to explore interventions that could potentially ameliorate the impact of placental pathology and enhance the neurological resilience of neonates facing the challenges of congenital heart disease.

Further reading: Placental Pathology Contributes to Impaired Volumetric Brain Development in Neonates With Congenital Heart Disease. Doi: https://doi.org/10.1161/JAHA.123.033189

Powered by WPeMatico

FMGE June 2024 Registrations: Here is Eligibility Criteria

New Delhi- The National Board of Examination in Medical Sciences (NBEMS) recently invited applications for the Foreign Medical Graduate Examination (FMGE) June 2024. For candidates appearing for FMGE, NBE has also released an information bulletin detailing the Eligibility Criteria for the FMGE for June 2024.

FMGE for June 2024 will be conducted on 6th July 2024 on the computer-based platform at various testing centres across the country. The registration has already begun and will be valid till 11:55 pm on 20th May 2024. Candidates can submit the application form for FMGE June 2024 online on the official website of NBE.

Also Read: NBE Invites Online Applications For FMGE June 2024, Know how to apply

ELIGIBILITY CRITERIA

The candidate must meet/fulfil the following criteria-

1 He / She is a citizen of India or an Overseas Citizen of India.

2 The candidate should possess a primary medical qualification, which is confirmed by the Indian Embassy concerned, to be a recognized qualification for enrolment as a medical practitioner in the country in which the institution awarding the said qualification is situated.

3 The result of the final examination for the said primary medical qualification should have been declared on or before 30th April 2024. However, the candidates need to submit proof /documentary evidence that clearly establishes that the result of the final examination for such a primary medical qualification was declared on or before the cut-off date i.e. 30th April 2024. If the proof / documentary evidence submitted by the candidate does not clearly establish that the result of the final examination of his primary medical qualification was declared on or before 30th April 2024 and/or does not clearly specify that the candidate has been declared PASS/QUALIFIED in the final examinations in all mandatory required courses, the candidature shall be cancelled and the candidate shall be declared as ineligible.

4 As per Eligibility Requirement for Taking Admission in an Undergraduate Medical Course in a Foreign Medical Institution Regulation, 2002-

I The candidate should have obtained an ‘Eligibility Certificate’ from the National Medical Commission (or the erstwhile Medical Council of India). This requirement shall not be necessary in respect of Indian citizens or Overseas Citizens of India who have acquired the medical qualifications from foreign medical institutions before 15.03.2002 or have obtained admission to a foreign medical institution either before 15.03.2002 or during 15.05.2013 to 03.01.2014 (both dates included).

II In terms of the notification published in the Gazette of India, “Indian Citizens/Overseas Citizens of India intending to obtain primary medical qualification from any medical institution outside India, on or after May 2018, shall have to mandatorily qualify the ‘National-Eligibility-cumEntrance Test for Admission to MBBS course’. The result of the ‘National- Eligibility-cum-Entrance Test for Admission to MBBS course’ shall be deemed to be treated as the Eligibility Certificate for such persons, provided that such persons fulfil the Eligibility Criteria for admission to the MBBS course prescribed in the Regulations on Graduate Medical Education, 1997.”

III In terms of notification published in the Gazette of India, “the result of NEET shall be valid for a period of three (3) years from the date of declaration of result, entitling a candidate to pursue MBBS or equivalent medical course including pre-medical/language course, if any, followed by MBBS or equivalent medical course.”

IV Applicants who are applying for FMGE producing their NEET-UG result in lieu of the Eligibility Certificate in terms of aforesaid notifications are accordingly advised to ensure that they fulfil the Eligibility Criteria for admission to the MBBS course prescribed in the Regulations on Graduate Medical Education, 1997. In the event an applicant qualifying FMGE is later found, at the time of seeking registration with a medical council, not to be fulfilling the Eligibility Criteria for admission to the MBBS course as prescribed in the Regulations on Graduate Medical Education, 1997, his /her candidature and result for said FMGE shall be deemed to be cancelled.

Also Read: NEET PG 2024 on June 23, FMGE rescheduled: NBE releases tentative exam calendar for forthcoming exams, All details here

5 It is the sole responsibility of the candidate that he/she has fulfilled the stipulations/criteria prescribed in Graduate Medical Education Regulations (GMER), 1997 and Eligibility Requirement before taking admission in the undergraduate medical course in Foreign Medical Institution Regulations, 2002, enumerated herein below, but not limited to the following-

I He/she fulfilled the age criterion prescribed for admission to the MBBS course in the above regulations at the time of joining the Primary Medical Qualification.

II He/she fulfilled the eligibility criteria for admission to the MBBS course in India as prescribed in the Graduate Medical Education Regulations, 1997, i.e., minimum qualifying marks criteria in Physics, Chemistry, Biology and English, including relaxed criteria in case the candidate belongs to a reserved category (SC/ST/OBC) or a PwD.

III He/she is in possession of the relevant caste certificate (SC/ST/OBC) from a competent authority issued at the time of his/her admission to Primary Medical Qualification, in case he/she has claimed any relaxed criteria towards minimum qualifying marks in Physics, Chemistry, Biology and English.

6 Candidate seeking provisional or permanent registration in India shall not have to qualify the Screening Test if he/she holds an undergraduate medical qualification from Australia/Canada/New Zealand/United Kingdom/United States of America and the holder thereof has also been awarded a Post Graduate medical qualification in Australia/ Canada/New Zealand/ United Kingdom/United States of America and has been recognised for enrolment as medical practitioner in that country.

7 Eligibility of candidates who have obtained their primary medical qualification from Pakistan shall be subject to their security clearance from the Ministry of Home Affairs (MHA), Govt of India. The Ministry of Health & Family Welfare, Govt of India through a vide Letter has directed that-

I In view of national security considerations, no Indian student should go to Pakistan to study in any field. Henceforth, no student should be eligible for appearing in FMGE based on educational qualification (in any subject) acquired in Pakistan except those who had joined Pakistan degree colleges/institutions before November 2018 or later after obtaining security clearance from MHA till 13.04.2022.

II Migrants and their children who have acquired medical degree or higher education from Pakistan and have been granted Indian citizenship by India would not require additional security clearance from MHA for appearing in FMGE or seeking employment including registration with NMC and admission in any educational institutions/colleges including medical institutions/colleges in India. Such security vetting is carried out while granting citizenship.

III The result of FMGE for candidates who have obtained their Primary Medical Qualification from Pakistan shall only be declared if such candidates have been given security clearance by MHA, Govt of India. Migrants from Pakistan are required to submit their Certificates of Registration for Citizenship of India issued by MHA, Govt of India while applying for FMGE.

Also Read: NEET PG 2024 on June 23, FMGE rescheduled: NBE releases tentative exam calendar for forthcoming exams, All details here

8 Candidates may also refer to Screening Test Regulations, 2002 & all its amendments, Regulations on Graduate Medical Education and Eligibility Certificate Regulations before applying for FMGE and confirming their eligibility for registration as medical practitioners in India.

9 Pursuant to the recommendations of the NMC through its vide letter has the approval of the Ministry of Health and Family Welfare (MoHFW), Govt of India, only eligible candidates will be allowed to appear in the FMGE who have both the Eligibility Certificate (if applicable) and the Provisional Pass Certificate/Degree Certificate of Primary Medical Qualification.

10 Candidates are therefore advised to apply for FMGE only if they possess with them all the documents required to apply for the examination, including the Eligibility Certificate (if applicable) and the Provisional Pass Certificate/ Degree Certificate of their Primary Medical Qualification duly apostilled/ attested by Indian Embassy concerned.

11 Candidates who fail to submit the documents for FMGE will not be allowed to appear in the examination and will be declared ineligible to appear.

12 The Role of NBEMS is limited to conducting the FMGE and to handover the result to all State Medical Councils (SMCs) in India. The eligibility of a candidate to appear in FMGE shall be solely determined based on information and documents furnished by the candidate in his/her application form which shall be treated as correct & factual as per the declaration of the candidate. The eligibility for registration as a medical practitioner, however, shall be determined by SMCs at the time of provisional/permanent registration of a candidate.

13 ।Any instances of furnishing incorrect information/documents detected during any stage of the examination process and/or subsequently while/after seeking registration with a medical council will automatically disqualify the candidate for the FMGE and for any consequential registration/ employment/ education. Further, if such instances go undetected during any verification process but, are detected in subsequent years, such disqualification will take place with a retrospective effect.

14 Eligibility of candidates who shall be issued admit cards for the examination shall be purely provisional and if ineligibility is detected at any stage of FMGE, the candidature shall be cancelled even if the result has been declared and/or the Pass Certificate has been issued.

IMPORTANT DATES

S.NO

PARTICULARS

DATES

1

Online Submission of Applications.

29th April 2024 to 20th May 2024 (Till 11:55 PM).

2

Edit Window for All Payment Success Applications (Any information/documents can be edited except Name, Nationality, Email, Mobile number and Test City).

24th May 2024 to 28th May 2024.

3

Final Edit Window to rectify Deficient/Incorrect Images (No further opportunity shall be given)-

1 Photograph.

2 Signatures.

3 Thumb Impression.

7th June 2024 to 10th June 2024.

4

Opportunity to rectify deficiencies related to documents uploaded in the application-

1 Primary Medical Qualification Certificate (PMQC).

2 Apostille/Attestation of PMQC by the Indian embassy concerned.

3 Eligibility Certificate or Admission Letter.

4 Proof of Citizenship.

Through Online Deficient Document Submission Portal.

The portal will be closed on 14th June 2024 at 11:55 PM.

5

Final opportunity to rectify deficiencies related to documents uploaded in the application (A list of such candidates will be published on the NBEMS website).

21st June 2024 (11 AM onwards) to 24th June 2024 (Till 11:55 PM).

6

Issue of Admit Card.

1st July 2024.

7

Examination Date.

6th July 2024.

8

Declaration of Result.

By 6th August 2024.

Powered by WPeMatico

Conduct bridging CT, prove efficacy, safety: CDSCO Panel Tells Glenmark on Roflumilast Cream of additional strength, indication

New Delhi: Citing that Glenmark Limited should conduct bridging clinical trials to prove the efficacy and safety of the Roflumilast Cream 0.3%w/w (additional strength and indication) on the Indian population, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined to submit Phase-III clinical trial protocol to CDSCO for further review by the committee.

This came after Glenmark Limited presented the proposal for a grant of permission to manufacture and marketing of Roflumilast cream 0.3%w/w(additional strength & indication) along with justification and comparative in-vitro bioequivalence data between Glenmark’s test product and reference product (ZRYVE Cream) and requested for waiver of Phase-III clinical trial & Bio-equivalence study before the committee.

The firm informed that the proposed formulation Roflumilast topical cream 0.3%w/w was already approved in the USA on 29.06.2022 and Canada on 27.04.2023 for the same indication.

Roflumilast topical cream is used to treat plaque psoriasis, which is a form of skin disease with red patches and white scales that do not go away. It is also used to treat seborrheic dermatitis. Plaque psoriasis is a chronic dermatologic autoimmune disease that affects adults and children. Roflumilast 0.3% cream is currently the only topical phosphodiesterase 4 inhibitor indicated for the treatment of plaque psoriasis in patients 12 years or older.

Roflumilast inhibits the phosphodiesterase 4 inhibitor enzyme leading to the accumulation of cyclic adenosine monophosphate, which suppresses the inflammatory mediators interferon-γ and tumor necrosis factor-α.

At the recent SEC meeting for the Dermatology and Allergy held on 16th April 2024, the expert panel reviewed the proposal for grant of permission to manufacture and marketing of Roflumilast cream 0.3%w/w (additional strength & indication) along with justification and comparative in-vitro bioequivalence data between Glenmark’s test product and reference product (ZRYVE Cream) and request for waiver of Phase-III clinical trial and Bio-equivalence study before the committee.

After detailed deliberation, the committee recommended that the firm should conduct bridging clinical trials to prove the efficacy and safety of the proposed formulation on the Indian population.

Accordingly, the expert panel suggested that the firm should submit the Phase-III clinical trial protocol to CDSCO for further review by the committee.

Also Read:Lupin Digital Health’s Lyfe Platform gets Class C Medical Device license from CDSCO

Powered by WPeMatico

Glenmark Pharma gets USFDA nod for Acetaminophen and Ibuprofen Tablets

New Jersey: Glenmark Pharmaceuticals Ltd. has received final approval from the United States Food & Drug Administration (U.S. FDA) for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), determined by the FDA to be bioequivalent 1 to Advil 2 Dual Action with Acetaminophen Tablets, 250 mg/125 mg (OTC), of Haleon US Holdings, LLC.

Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics Inc., USA.

According to Nielsen syndicated data for the latest 52 weeks period ending March 23, 2024, the Advil Dual Action with Acetaminophen Tablets, 250 mg/125 mg (OTC) market 3 achieved annual sales of approximately $84.1 million*.
Glenmark’s current portfolio consists of 195 products authorized for distribution in the U.S. marketplace and 52 ANDA’s pending approval with the U.S. FDA.
“In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio,” the Company stated.
Glenmark Pharmaceuticals Ltd. is a research‐led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. 

Powered by WPeMatico

Horlicks rebranded as Functional Nutritional Drink

In response to directives from the Union Ministry of Commerce and Industry, Hindustan Unilever has rebranded its ‘health food drinks’ category, renaming it as ‘functional nutritional drinks’ (FND). This decision, prompted by concerns over categorization on e-commerce platforms, affects prominent brands like Horlicks and Boost. Ritesh Tiwari, the company’s chief financial officer, stated that this rebranding reflects a more accurate depiction of the products. The move also aligns with efforts to tap into the underexplored market potential of the category.

Hindustan Unilever aims to expand its consumer base, usage, and benefits within the FND segment. Additionally, the company is observing promising growth in its premium offerings, particularly those tailored for diabetes management and women’s health. The initiative comes in light of the National Commission for Protection of Child Rights’ observation that there is no defined category for ‘health drinks’ under the Food Safety and Standards Act 2006. Further, the Food Safety and Standards Authority of India (FSSAI) has cautioned against misleading categorizations such as labeling dairy, cereal, or malt-based beverages as ‘health’ or ‘energy’ drinks on e-commerce platforms.

Powered by WPeMatico

NMC pulls up defaulting medical colleges, asks to submit stipend data immediately

New Delhi: Observing that many medical colleges have not yet submitted the requisite details of the stipend paid to the MBBS, PG medical students and resident doctors for the academic year 2023-2024, the National Medical Commission (NMC) has directed the defaulting institutes to submit the stipend data immediately by 02.05.2024.

The Apex Medical Commission has warned the defaulting colleges that failure on the part of the colleges to submit the data will be viewed seriously, adding that NMC would take strict action against the colleges for non-compliance.

“Accordingly, all defaulting colleges are requested to forward/ submit their stipend payment details for FY-2023-24 to only the prescribed E-mail ID by 02.05.2024 invariably,” NMC mentioned in the notice dated 30.04.2024.

NMC had asked the institutes to submit the stipend data after the Supreme Court took cognizance of the matter and issued directions to the Commission to submit the details of the stipend paid to MBBS interns in all the medical colleges across all the States within four weeks.

Also Read: Submit Details of Stipend paid to MBBS Interns by Medical Colleges in All States: SC Directs NMC

Medical Dialogues had earlier reported that NMC had given a deadline to the medical colleges to submit the details of the stipend paid to their UG Interns, Post-Graduate Residents, and Senior Residents or PGs in Super Specialty for the financial year 2023-24 by 23rd April 2024. The medical colleges were directed to submit the details of their name and address, the amount of stipend paid by the State Government, and the month-wise details of the stipend paid to the MBBS interns, 1st/2nd/3rd-year Post-Graduate Residents, and 1st/2nd/3rd-year Senior Residents or PGs in Super Specialty for the academic year 2023-2024.

NMC provided a similar annexure for the details of the stipend paid to the medical students for the academic year 2024-2025. However, in this regard, the Commission had directed the concerned colleges to update these details on the website of the institute every month (by 5th of every month). The colleges had been asked to submit the complete statement to the NMC at the end of each financial year.

Also Read: Submit details of stipend paid to MBBS interns, resident doctors: NMC issues deadline to all medical colleges

Referring to its earlier directions, NMC in the notice issued today i.e. on 30.04.2024 mentioned, “Hon’ble Supreme Court of India in the WP(C) No.730/2022 & other cases, vide their orders dt. 16-09-2023 and 01-04-2024, has directed NMC to submit the details of stipends paid to the Medical Interns and residents. Accordingly, all the Health Institutions/Medical Colleges were directed, vide Public Notice dated 16-04- 2024, to submit to NMC, the details of stipend paid to their UG interns, PG residents and senior residents or PGs in Super Specialty for the financial year 2023-24.”

“Further, directed to upload the details for financial year 2024-25 onwards on the website of the Medical College/ Medical Institutions concerned and also required to be updated on monthly basis (by 5 th of every month) as per the Annexure-2 and at the end of the financial year, the complete statement be submitted to NMC on E-mail ID: stipend24-25@nmc.org.in,” it further mentioned.

Warning of strict action against the defaulting colleges, the Commission informed about the extended deadline and asked the medical colleges to submit the requisite information for 2023-2024 by 02.05.2024. 

“It is observed that many colleges have not yet forwarded the requisite data/ information in the prescribed format to the designated E-mail ID for the data relating to FY-2023-24 viz. “stipend23-24@nmc.org.in“. In view of the directions of the Supreme Court for submitting the data within 4 weeks, all defaulting Medical Colleges are hereby requested to immediately submit requisite information/data for FY-2023-24 by 02.05.2024 without any further delay and failure on the part of the colleges in submitting the data will be viewed seriously and strict action against the colleges will be taken,” the notice mentioned.

Recently, while commenting on the issue of stipend paid to the medical student, the NMC Secretary Dr. B Srinivas told Medical Dialogues that the medical colleges would have to upload monthly reports on the stipend given by them to the medicos or face severe action.

To view the NMC notice, click on the link below:

https://medicaldialogues.in/pdf_upload/nmc-notice-30042024-237233.pdf

Also Read: Medical colleges will have to upload monthly stipend data or Face Action: NMC Secretary

Powered by WPeMatico